BSX Stock Performance, Insider Transaction and News

BSX - Boston Scientific Corporation

Market Cap	72.78B	P/E	85.80	EPS this Y	17.60%	Ern Qtrly Grth	20.00%
Income	1.83B	Forward P/E	22.60	EPS next Y	13.30%	50D Avg Chg	-4.00%
Sales	15.23B	PEG	2.72	EPS past 5Y	14.91%	200D Avg Chg	5.00%
Dividend	N/A	Price/Book	4.08	EPS next 5Y	12.84%	52W High Chg	-8.00%
Recommedations	1.70	Quick Ratio	0.95	Shares Outstanding	1.47B	52W Low Chg	34.00%
Insider Own	0.19%	ROA	4.81%	Shares Float	1.47B	Beta	0.80
Inst Own	92.79%	ROE	9.32%	Shares Shorted/Prior	12.20M/10.74M	Price	50.62
Gross Margin	68.69%	Profit Margin	12.00%	Avg. Volume	7,694,100	Target Price	88.21
Oper. Margin	19.39%	Earnings Date	Oct 24	Volume	7,777,369	Change	-2.45%

Healthcare | Medical Devices | United States

About Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corporation News

11/20/24	Boston Scientific Corporation (BSX)’s Breakthroughs: A Hidden Gem in Billionaire Ken Griffin’s Portfolio
11/19/24	Reasons to Retain BSX Stock in Your Portfolio for Now
11/19/24	BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
11/19/24	Boston Scientific Stock Set to Gain From Completion of Axonics Deal
11/18/24	Inside a $400 billion bet on the brain-computer interface revolution
11/18/24	Here's Why We Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today
11/18/24	Boston Scientific’s Watchman could be new option for patients post ablation: study
11/18/24	The PFA race is heating up. Here’s where the market stands after J&J’s approval.
11/18/24	Boston Scientific reports outcomes from trial of LAAC device
11/16/24	Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
11/15/24	HAE or BSX: Which Is the Better Value Stock Right Now?
11/15/24	Boston Scientific Closes Acquisition of Axonics, Inc.
11/15/24	Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
11/15/24	Boston Scientific closes $3.7B Axonics deal after lengthy review
11/15/24	Should You Retain Hologic Stock in Your Portfolio Now?
11/14/24	Strategic Moves in Caxton Associates' Portfolio Highlight Tesla's Prominence
11/14/24	Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock
11/14/24	MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
11/14/24	IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
11/14/24	Investing in Boston Scientific (NYSE:BSX) three years ago would have delivered you a 113% gain

BSX Chatroom

jagadakku Posted - 2 hours ago

@Ludlowj @HereForFunsies $BAYRY I've been watching this for a while because of the company and was shocked to see the price but there was a company I worked for once that cratered to sub 5 $BSX and then bounced back .. point is, patience will win out. I'm still waiting to get in on this.. gluck and stay strong

MakingMeMeoutofME Posted - 23 hours ago

$MDT down post results just like $BSX post results 88 to 81 then to 91 in less than a month were growing eps 2H BIGGER we do

bullishbears Posted - 1 day ago

🧠 Neuralink: Innovating the Future of Brain Tech 🧬 While Neuralink (Elon Musk’s brain-implant company) is private, its groundbreaking work in neurotechnology has everyone watching. You can’t invest in Neuralink, but there are public companies making strides in similar spaces: 💡 $MDT – Medtronic, a leader in neuromodulation devices. 💡 $IART – Integra LifeSciences, specializing in neuroscience solutions. 💡 $BSX – Boston Scientific, innovating in neural and brain health tech. The neurotech revolution is just beginning—these companies are key players to watch! 📈 https://bullishbears.com/neuralink-stock/

MakingMeMeoutofME Posted - 1 day ago

$MDT which Wall Street firm is upgrading the stock to 100-110 target avg EPS for 2H is 1.49 per share per qtr. off 1.23 and 1.26 in 1H stock is going to be bought $ISRG $ABT $SYK $BSX no brainer for 2-3 month

MakingMeMeoutofME Posted - 1 day ago

$MDT breaks 85.60 it can run to 88.80 $BSX $ABT $SYK 3.25 divi 2H growth is here 5.47 eps and 5.85-5.90 next

GuerillaStockTrading Posted - 1 day ago

💡 Innovate, Elevate, Investigate: Boston Scientific's Strategy for Growth 🌐 $BSX #MedTech https://www.guerillastocktrading.com/bsx-stock-forecast/

11thestate Posted - 2 days ago

$BSX has agreed to a $38.5M settlement with $BSX investors to resolve claims that the company made misleading statements about its heart valve product, the LOTUS Edge. Even if you missed the deadline, if you bought between September 16, 2020, and November 16, 2020, you can still file a late claim: https://11thestate.com/cases/boston-scientific-shareholder-settlement

MakingMeMeoutofME Posted - 2 days ago

$MDT 5.80 in FY26 at 17x = 100 per share $BSX $ABT $SYK 22-33x

MuscleStocks Posted - 2 days ago

$BSX New highs after finding support at the rising 20 day ema

JackDarwin Posted - 2 days ago

$BSX Bullish Gap Up Formed.

Doozio Posted - 2 days ago

$BSX INTA 🧠⏰♾️

Doozio Posted - 2 days ago

$BSX NOW just waiting on 🐱in da FUTUre of this 🧠⏰ GME INTA 🧠⏰♾️

MarkNewtonCMT Posted - 2 days ago

Despite the persistent underperformance in Healthcare recently, stocks like $BSX continue to shine- Today managed to clear the recent consolidation & keeps Boston Scientific within a strong uptrend @IBDinvestors @marketsurge Selectivity remains important in this sector

MakingMeMeoutofME Posted - 2 days ago

$MDT 14.50 x FY 2026 EPS 3.20 % divi $SYK $ABT $BSX all 22+ going to 100

kylevallans Posted - 2 days ago

$BSX

contangoz Posted - 2 days ago

CHART of day $bsx

MakingMeMeoutofME Posted - 2 days ago

$MDT EPS in AM 1.24 on 8.26B with 5.45 eps estimate for FY25(APR) and 5.85 (FY26) trades 16x and 3% dividend while $BSX $ABT $ZBH $SYK all Trade at 20-40x

JasonCO Posted - 2 days ago

$BSX

IsabellaDC Posted - 2 days ago

Monday 11/18 All time leaders: $NFLX $SYK $LPX $BSX $LYV and so on.

Monkey_Banana_Genius Posted - 3 days ago

$BSX 💪

JFDI Posted - 3 days ago

Sugar momma bring me to the promised land $BSX

Randox123 Posted - 3 days ago

$BSX positive option trial results!

Stockosaurus Posted - 6 days ago

$BSX $CRM damn E*Trade! I was about to say! I was ready to load the boat…. But not today, will just keep what I got… lol

TheProphetOfProfit Posted - 1 week ago

$BSX multi-year uptrend channel on the weekly, $90+ before any pullback.

heyyo11 Posted - 1 week ago

$PRCT time to buy back in???? or a buyout $ISRG $JNJ $BSX

jeffmeredith Posted - 1 week ago

$BSX $89.30 ath. Hope you added in $80s on Oct 30.

Hero0602 Posted - 1 week ago

$BSX And commence going up.

JFDI Posted - 1 week ago

$BSX

MakingMeMeoutofME Posted - 1 week ago

$MDT I feel an upgrade or 2 before Friday $ABT $SYK $BSX medical device plays 100 target on CEO's positive comments

MakingMeMeoutofME Posted - 1 week ago

$MDT breakout of 88.88 and we see 90 $SYK $ABT $BSX

Analyst Ratings

Evercore ISI Group	Outperform	Oct 1, 24
Raymond James	Strong Buy	Sep 4, 24
Citigroup	Buy	Aug 22, 24
Barclays	Overweight	Aug 22, 24
Raymond James	Strong Buy	Jul 25, 24
Deutsche Bank	Hold	Jul 25, 24
RBC Capital	Outperform	Jul 25, 24
JP Morgan	Overweight	Jul 25, 24
Canaccord Genuity	Buy	Jul 25, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Mirviss Jeffrey B.	EVP&Pres, Periph Int.. EVP&Pres, Periph Intervent	Jan 09	Sell	59.25	15,172	898,941	56,588	01/10/24
Mirviss Jeffrey B.	EVP&Pres, Periph Int.. EVP&Pres, Periph Intervent	Jan 09	Option	16.31	15,172	247,455	71,760	01/10/24
Mirviss Jeffrey B.	EVP&Pres, Periph Int.. EVP&Pres, Periph Intervent	Jan 04	Sell	58.4	15,000	876,000	56,588	01/05/24
Mirviss Jeffrey B.	EVP&Pres, Periph Int.. EVP&Pres, Periph Intervent	Jan 04	Option	16.31	15,000	244,650	71,588	01/05/24
Fitzgerald Joseph Michael	EVP & Group Pres, Ca.. EVP & Group Pres, Cardiology	Dec 29	Sell	57.5	81,940	4,711,550	174,241	01/02/24
Fitzgerald Joseph Michael	EVP & Group Pres, Ca.. EVP & Group Pres, Cardiology	Dec 29	Option	8.16	79,988	652,702	196,040	01/02/24
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Oct 09	Sell	52.09	113,355	5,904,662	1,498,922	10/10/23
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Oct 09	Option	14.7	113,355	1,666,318	1,612,277	10/10/23
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Sep 15	Sell	53.95	11,671	629,650	57,058	09/15/23
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Sep 15	Option	14.7	6,408	94,198	68,729	09/15/23
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Sep 12	Option	14.7	113,355	1,666,318	1,612,277	09/12/23
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Sep 12	Sell	53.91	113,355	6,110,968	1,498,922	09/12/23
Butcher Arthur C	EVP& Grp Pres, MedSu.. EVP& Grp Pres, MedSurg & APAC	Aug 21	Sell	50.4032	6,600	332,661	11,396	08/22/23
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Jul 17	Sell	52.85	11,671	616,812	67,584	07/18/23
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Jul 17	Option	14.7	6,408	94,198	79,255	07/18/23
Thepaut Eric Francis Yves	EVP & Pres, Eur, Mid.. EVP & Pres, Eur, Mid-East, Afr	May 02	Sell	52.49	83,401	4,377,718	12,269	05/03/23
Thepaut Eric Francis Yves	EVP & Pres, Eur, Mid.. EVP & Pres, Eur, Mid-East, Afr	May 02	Option	12.89	30,688	395,568	95,670	05/03/23
Brennan Daniel J.	EVP and CFO EVP and CFO	Feb 15	Sell	47.14	7,572	356,944	276,316	02/16/23
Brennan Daniel J.	EVP and CFO EVP and CFO	Feb 15	Option	3.7	11,725	43,382	285,107	02/16/23
Butcher Arthur C	EVP& Grp Pres, MedSu.. EVP& Grp Pres, MedSurg & APAC	Feb 03	Sell	48.74	27,000	1,315,980	23,392	02/06/23
Butcher Arthur C	EVP& Grp Pres, MedSu.. EVP& Grp Pres, MedSurg & APAC	Feb 03	Option	16.79	15,034	252,421	50,392	02/06/23
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Dec 15	Sell	46.6224	7,500	349,668	87,413	12/15/22
Mirviss Jeffrey B.	EVP&Pres, Periph Int.. EVP&Pres, Periph Intervent	Dec 12	Sell	46.7500	11,080	517,990	88,479	12/13/22
Thepaut Eric Francis Yves	EVP & Pres, Eur, Mid.. EVP & Pres, Eur, Mid-East, Afr	Nov 18	Sell	42.7216	14,952	638,773	57,534	11/21/22
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Nov 07	Option	10.24	125,827	1,288,468	1,893,492	11/08/22
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Nov 07	Sell	41.97	125,827	5,280,959	1,767,665	11/08/22
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Aug 15	Sell	42.0346	7,500	315,260	117,413	08/15/22
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Aug 08	Option	10.24	125,828	1,288,479	2,258,950	08/09/22
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Aug 08	Sell	40.97	125,828	5,155,173	2,133,122	08/09/22
Connors Nelda J	Director Director	Aug 02	Sell	41.5800	16,088	668,939	4,877	08/04/22
Thepaut Eric Francis Yves	EVP & Pres, Eur, Mid.. EVP & Pres, Eur, Mid-East, Afr	Aug 01	Sell	40.9900	20,676	847,509	72,486	08/03/22
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Jul 18	Sell	38.0000	7,500	285,000	124,913	07/18/22
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Jun 24	Sell	38.0000	7,500	285,000	132,413	06/27/22
Mirviss Jeffrey B.	EVP&Pres, Periph Int.. EVP&Pres, Periph Intervent	Apr 19	Sell	45.5000	10,989	500,000	119,961	04/20/22
Carruthers Wendy	EVP, Human Resources EVP, Human Resources	Apr 14	Sell	44.4691	7,500	333,518	147,413	04/14/22
Butcher Arthur C	EVP&Pres, Asia Pacif.. EVP&Pres, Asia Pacific	Mar 29	Option	16.31	5,411	88,253	40,547	03/31/22
Butcher Arthur C	EVP&Pres, Asia Pacif.. EVP&Pres, Asia Pacific	Mar 29	Sell	45	10,269	462,105	30,278	03/31/22
Meredith Ian T	EVP Global Chief Med.. EVP Global Chief Med Officer	Mar 28	Sell	43.6800	6,588	287,764	28,082	03/29/22
Pierce David A	EVP Pres MedSurg EVP Pres MedSurg	Feb 15	Option	0	2,769		2,769	02/17/22
Pierce David A	EVP Pres MedSurg EVP Pres MedSurg	Feb 15	Sell	43.81	1,956	85,692		02/17/22
Brennan Daniel J.	EVP and CFO EVP and CFO	Feb 15	Option	3.14	16,340	51,308	278,364	02/17/22
Brennan Daniel J.	EVP and CFO EVP and CFO	Feb 15	Sell	43.59	21,323	929,470	266,177	02/17/22
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Sep 08	Sell	44.57	201,041	8,960,397	2,081,822	09/08/21
Mahoney Michael F	Chairman, President.. Chairman, President & CEO	Sep 08	Option	6.84	201,041	1,375,120	2,282,863	09/08/21